Latest News for: lilly

Edit

Eli Lilly makes a deal outside obesity. Plus, another word of caution on Nvidia

CNBC 17 Nov 2026
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading ... .
Edit

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

Morgan Citizen 17 Nov 2026
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward ... .
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Eli Lilly and Company)

Public Technologies 17 Nov 2026
) FORM 4 ... See Instruction 1(b) ... OMB Number ... 0.5 ... ELI LILLY & Co [LLY] 5 ... LILLY CORPORATE CENTER 3 ... LILLY CORPORATE CENTER ... Eli Lilly and Company published this content on November 17, 2026, and is solely responsible for the information contained herein.
Edit

Semper Fi & America's Fund Receives $10 Million Grant from Lilly Endowment to Strengthen Long-Term Support for Military Families

PR Newswire 17 Nov 2026
16, 2026 /PRNewswire/ -- Semper Fi & America's Fund (The Fund) has been awarded a $10 million grant from Lilly Endowment Inc ... "We are deeply grateful to Lilly Endowment for this extraordinary ...
Edit

Lilly obesity drug Zepbound helped adolescents lose weight in study

Indianapolis Business Journal 16 Nov 2026
Lilly is playing catch up in the adolescent segment of the multibillion-dollar obesity market it otherwise dominates. ... .
Edit

Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients ...

The Eagle-Tribune 16 Nov 2026
Calytrix Bio's potentially best-in-class preclinical program is a novel biparatopic antibody designed to deliver pan-mutant calreticulin activity ... .
Edit

Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet

The Lufkin News 16 Nov 2026
Nov 16 (Reuters) - Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers ....
Edit

Lilly to buy Calytrix Bio for up to $1.5 billion

The Lufkin News 16 Nov 2026
Nov 16 (Reuters) - Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday ....
Edit

Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

Wall Street Journal 16 Nov 2026
Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers ... .
Edit

Final Trades: Berkshire Hathaway, Cisco and Eli Lilly

CNBC 16 Nov 2026
The Investment Committee give you their top stocks to watch for the second half ... .
Edit

Alteogen's Obesity Drug Surpasses Eli Lilly's in Half-Life, Weight Regain

Chosun Ilbo 16 Nov 2026
pharmaceutical company Eli Lilly’s next-generation obesity treatment candidate in animal testing, along with a lower rate of weight regain after discontinuation.
Edit

Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving ...

My Horry News 15 Nov 2026
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes ....
×